drugset / Trial / NCT00072085
Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic Melanoma
RandomizedTreatment
Summary
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: This randomized phase II trial is studying immunization using two different gp100 protein vaccines to compare how well they work in treating patients with metastatic melanoma.
Timeline
- Start
- 2003-09
- Primary completion
- —
- Completion
- 2006-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DISOMOTIDE | Peptide | — | Subcutaneous |
| Subject | recombinant gp100 protein (184V) | Protein / enzyme biologic | — | Subcutaneous |
| Background | aldesleukin | Protein / enzyme biologic | — | Intravenous |
| Background | incomplete Freund's adjuvant | Other / unclassified | — | Subcutaneous |